Beta-amyloid, human

The accumulation of the extracellular beta-amyloid protein (which is also referred to as Aβ plaques) is one fundamental neuropathological hallmark of AD. To date, beta-amyloid is considered as being one of the most established biomarkers for the progression of AD.

Among the various beta-amyloid isoforms found in CSF, Aβ42 is considered as one of the key pathological biomarkers in terms of assessment for AD diagnosis. Aβ42 forms aggregation into fibrils and extracellular plaques in the brain, resulting in a lower level of Aβ42 in the CSF. Therefore, Aβ42 provides a predictive value for AD, which can be used in both the prodromal and dementia stage of AD.

At HyTest, we provide a selection of well­characterized mouse monoclonal antibodies for the detection of Aβ42 in human CSF. These antibodies were developed against synthetic peptides that correspond to fragments of the Aβ42 sequence.

Learn more:
Cat# 4BA3:Beta-amyloid, human, antibody